Related Experiment Video
Updated: Jun 15, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Aliskiren: a new drug for an old problem
Vivencio Barrios1, Carlos Escobar
1Department of Cardiology, Hospital Ramón y Cajal, Carretera de Colmenar Viejo, Madrid, Spain. vbarriosa@meditex.es
Cardiovascular & Hematological Agents in Medicinal Chemistry
|March 10, 2010
Summary
Direct renin inhibitors like aliskiren offer a novel approach to managing hypertension-related organ damage. Evidence suggests aliskiren may provide benefits, alone or in combination, where other renin-angiotensin system inhibitors fall short.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- The renin-angiotensin-aldosterone system (RAAS) is crucial in hypertension and target organ damage.
- Conventional RAAS inhibitors have limitations due to compensatory renin increases.
- Dual RAAS inhibition trials show increased adverse events without added benefit.
Purpose of the Study:
- To analyze current evidence on aliskiren, a direct renin inhibitor.
- To evaluate aliskiren's efficacy and safety, alone and in combination therapies.
Main Methods:
- Review of existing clinical trial data and scientific literature.
- Analysis of aliskiren's mechanism of action and clinical outcomes.
Main Results:
- Aliskiren directly inhibits renin, bypassing compensatory mechanisms.
- Promising results observed with aliskiren monotherapy and combination therapy.
Conclusions:
- Aliskiren represents a novel therapeutic strategy for hypertension management.
- Further research is warranted to fully elucidate aliskiren's role in clinical practice.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...